Pharmaceutical

Five things for pharma marketers to know: Monday, August 14, 2017

Five things for pharma marketers to know: Monday, August 14, 2017

Merck CEO leaves Trump's manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Friday, July 28, 2017

Five things for pharma marketers to know: Friday, July 28, 2017

Drugmakers inconsistently share clinical trial data; AstraZeneca's share price falls after Mystic results; some pregnancy apps share info with marketers

Otsuka's April Mitchell on leading versus managing

Otsuka's April Mitchell on leading versus managing

When you've figured out the difference, people will walk through fire for you, a mentor once told her.

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Half of clinical-trial sites offer free transportation to patients

Half of clinical-trial sites offer free transportation to patients

Consent forms and reimbursement are the main deterrents of offering the service.

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative